Conversely, even after 18 months of rilonacept treatment and despite the absence of pericarditis signs and symptoms (ie, absence of pain, CRP elevation, pericardial rub, ECG changes, or pericardial effusion) and the presence of only none/trace LGE in CMRs while on therapy, suspension of rilonacept treatment in these patients yielded a 75% (6/8) recurrence rate, likely due to an unmasking of the still‐persistent underlying autoinflammatory processes that had been previously quenched by the interleukin‐1‐trap mechanism of rilonacept. This evidence concerns the gene CRP and pericarditis.